NCT01266083View on ClinicalTrials.gov

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 14, 2011

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

Galinpepimut-S

Galinpepimut-S admixed with the adjuvant Montanide following specified schedule

BIOLOGICAL

GM-CSF

subcutaneous injection

OTHER

Montanide

adjuvant

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

Sellas Life Sciences Group

INDUSTRY

NCT01266083 - WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) | Biotech Hunter | Biotech Hunter